Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

830 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved two-year outcomes after drug-eluting versus bare-metal stent implantation in women and men with large coronary arteries: importance of vessel size.
Hansen KW, Kaiser C, Hvelplund A, Soerensen R, Madsen JK, Jensen JS, Pedersen SH, Eberli FR, Erne P, Alber H, Pfisterer M, Galatius S; BASKET PROVE Investigators. Hansen KW, et al. Among authors: jensen js. Int J Cardiol. 2013 Oct 25;169(1):29-34. doi: 10.1016/j.ijcard.2013.08.091. Epub 2013 Sep 8. Int J Cardiol. 2013. PMID: 24063913 Clinical Trial.
Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.
Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, Pedersen S, Jensen KS, Jensen JS. Iversen A, et al. Among authors: jensen ks, jensen js. J Interv Cardiol. 2011 Apr;24(2):105-11. doi: 10.1111/j.1540-8183.2010.00616.x. Epub 2010 Dec 22. J Interv Cardiol. 2011. PMID: 21175845 Free article. Clinical Trial.
Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Iversen AZ, Galatius S, Abildgaard U, Galloe A, Hansen PR, Pedersen S, Engstroem T, Jensen JS. Iversen AZ, et al. Among authors: jensen js. Cardiology. 2011;120(1):43-9. doi: 10.1159/000333117. Epub 2011 Nov 23. Cardiology. 2011. PMID: 22122887 Clinical Trial.
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design.
Jeger R, Pfisterer M, Alber H, Eberli F, Galatius S, Naber C, Pedrazzini G, Rickli H, Jensen JS, Vuilliomenet A, Gilgen N, Kaiser C. Jeger R, et al. Among authors: jensen js. Am Heart J. 2012 Feb;163(2):136-41.e1. doi: 10.1016/j.ahj.2011.08.023. Am Heart J. 2012. PMID: 22305828 Clinical Trial.
Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease.
Wanitschek M, Pfisterer M, Hvelplund A, De Servi S, Bertel O, Jeger R, Rickenbacher P, Iversen A, Jensen JS, Galatius S, Kaiser C, Alber H; BASKET-PROVE Investigators. Wanitschek M, et al. Among authors: jensen js. Int J Cardiol. 2013 Oct 3;168(3):2381-8. doi: 10.1016/j.ijcard.2013.01.257. Epub 2013 Feb 27. Int J Cardiol. 2013. PMID: 23453439 Clinical Trial.
Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes--results from the BASKET PROVE trial.
Jensen MT, Kaiser C, Sandsten KE, Alber H, Wanitschek M, Iversen A, Jensen JS, Pedersen S, Soerensen R, Rickli H, Zurek M, Fahrni G, Bertel O, De Servi S, Erne P, Pfisterer M, Galatius S; BASKET-PROVE investigators. Jensen MT, et al. Among authors: jensen js. Int J Cardiol. 2013 Oct 9;168(4):3802-6. doi: 10.1016/j.ijcard.2013.06.034. Epub 2013 Jul 11. Int J Cardiol. 2013. PMID: 23849965 Clinical Trial.
Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial.
Pedersen SH, Pfisterer M, Kaiser C, Jensen JS, Alber H, Rickenbacher P, Sørensen R, Iversen A, Jensen MT, Wadt K, Galatius S; BASKET-PROVE Investigators. Pedersen SH, et al. Among authors: jensen mt, jensen js. EuroIntervention. 2014 May;10(1):58-64. doi: 10.4244/EIJV10I1A11. EuroIntervention. 2014. PMID: 24694667 Free article. Clinical Trial.
830 results